Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 534.4 g/mol |
---|---|
Molecular Formula | C23H21F7N4O3 |
XLogP3 | 4.2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 6 |
Exact Mass | 534.15018768 g/mol |
Monoisotopic Mass | 534.15018768 g/mol |
Topological Polar Surface Area | 75.2 A^2 |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 810 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Aprepitant |
PubMed Health | Aprepitant (By mouth) |
Drug Classes | Antiemetic |
Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
Active Ingredient | Aprepitant |
Dosage Form | Capsule |
Route | Oral |
Strength | 125mg; 80mg; 40mg |
Market Status | Prescription |
Company | Sandoz |
2 of 4 | |
---|---|
Drug Name | Emend |
PubMed Health | Aprepitant (By mouth) |
Drug Classes | Antiemetic |
Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
Active Ingredient | Aprepitant; Fosaprepitant dimeglumine |
Dosage Form | Capsule; Powder |
Route | Intravenous; Oral |
Strength | eq 150mg base/vial; 125mg; 80mg; 40mg |
Market Status | Prescription |
Company | Merck; Merck And |
3 of 4 | |
---|---|
Drug Name | Aprepitant |
PubMed Health | Aprepitant (By mouth) |
Drug Classes | Antiemetic |
Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
Active Ingredient | Aprepitant |
Dosage Form | Capsule |
Route | Oral |
Strength | 125mg; 80mg; 40mg |
Market Status | Prescription |
Company | Sandoz |
4 of 4 | |
---|---|
Drug Name | Emend |
PubMed Health | Aprepitant (By mouth) |
Drug Classes | Antiemetic |
Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
Active Ingredient | Aprepitant; Fosaprepitant dimeglumine |
Dosage Form | Capsule; Powder |
Route | Intravenous; Oral |
Strength | eq 150mg base/vial; 125mg; 80mg; 40mg |
Market Status | Prescription |
Company | Merck; Merck And |
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?